Investors have funneled $275 million into a revamped biotech developing new psoriasis and psoriatic arthritis treatments that could be given just once or twice a year.
The new Oruka Therapeutics launched Wednesday through a reverse merger with ARCA biopharma, a Colorado biotech that has undergone several iterations over the last 30 years. With the merger, ARCA’s plans are being cast aside in favor of Oruka’s antibody medicines, which came from spinout-generator Paragon Therapeutics. Over the last two years, Paragon has spun out Apogee Therapeutics and Spyre Therapeutics.
Oruka will trade under the Nasdaq ticker “ORKA.”
Click this link for the original source of this article.
Author: Allison DeAngelis
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.